Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a ...

How much longer will state leaders ignore Connecticut’s slow-moving exodus? That’s a question that will become increasingly pertinent as the state’s tax base continues to shrink. Businesses — and, ...